Lataa...
Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression
Programmed death-ligand 1 (PD-L1) is a well-known immune checkpoint protein that helps cancer cells evade immune response. Anti-PD-L1 immune therapy has been approved for the treatment of several advanced human cancers. Therefore, further understanding of the regulatory mechanisms of PD-L1 is critic...
Tallennettuna:
| Julkaisussa: | Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6050079/ https://ncbi.nlm.nih.gov/pubmed/29789418 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-0040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|